Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab. Bonomi G, Griguolo G, Giarratano T, Zanghi F, et al. NPJ Breast Cancer 2025;11:132.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Bonomi G, Griguolo G, Giarratano T, Zanghi F, et al. Real-world outcomes of early-stage HER2-positive breast cancer patients treated with adjuvant paclitaxel and trastuzumab. NPJ Breast Cancer 2025;11:132.
PMID: 41298527